Phospho-NOS1 (Ser852) Antibody

What is the specificity of Phospho-NOS1 (Ser852) antibody?

Phospho-NOS1 (Ser852) antibody specifically detects endogenous levels of neuronal Nitric Oxide Synthase (nNOS/NOS1) only when phosphorylated at Serine 852 . The antibody is typically generated against a synthesized phospho-peptide derived from human nNOS around the phosphorylation site of Ser852, typically spanning amino acids 818-867 . Most commercially available antibodies are affinity-purified using epitope-specific immunogens and undergo sequential chromatography on phospho- and non-phospho-peptide affinity columns to ensure high specificity .

What are the validated applications for this antibody?

The Phospho-NOS1 (Ser852) antibody has been validated for multiple laboratory applications including:

When designing experiments, it is recommended to optimize these dilutions based on your specific sample type and detection system .

What is the typical molecular weight band observed for phosphorylated NOS1?

When performing Western blot analysis, researchers should expect to observe a band at approximately 130-160 kDa for phosphorylated NOS1 . Some variations in the observed band may occur depending on the species and tissue type being examined. The specific band can be validated by using a phospho-peptide blocking control, where pre-incubation with the phospho-peptide should eliminate the specific band .

How does phosphorylation at Ser852 regulate NOS1 activity?

Phosphorylation at Ser852 serves as a negative regulatory mechanism for NOS1 activity. Research has demonstrated that:

• Phosphorylation at Ser852 is associated with decreased NOS1 enzyme activity and reduced NO production

• Dephosphorylation of NOS1 at Ser852 correlates with increased nitric oxide (NO) and possibly H₂O₂ production

• In vascular cells, particularly in endothelial cells, dephosphorylation of nNOS at Ser852 contributes to endothelium-dependent vascular relaxation

This provides important mechanistic insights for researchers investigating nitric oxide signaling, particularly in the context of vascular function and cardiovascular diseases .

What signaling pathways regulate NOS1 Ser852 phosphorylation status?

The regulation of NOS1 Ser852 phosphorylation involves several key signaling components:

• Dephosphorylation pathway:

  • Acetylcholine (ACh) stimulation induces dephosphorylation of nNOS at Ser852 in aorta after 20 minutes of stimulation

  • This process is mediated primarily by Protein Phosphatase 1 (PP1), not PP2

  • The mechanism involves a cAMP/PKA-dependent pathway that activates PP1, leading to:

    • Dissociation of PP1 from its nuclear inhibitor (NIPP1)

    • Translocation of PP1 to the cytoplasm

    • Subsequent dephosphorylation of nNOS at Ser852

• PKA-dependent regulation:

  • PKA inhibition:

    • Abolishes PP1 translocation

    • Prevents nNOS Ser852 dephosphorylation

    • Decreases nNOS translocation to perinuclear region

  • 8-Br-cAMP (a PKA activator):

    • Reduces NIPP1/PP1 interaction

    • Stimulates PP1 translocation

    • Promotes nNOS Ser852 dephosphorylation

Understanding these pathways is crucial for researchers investigating the molecular mechanisms of nitric oxide signaling in various physiological and pathological conditions .

How should I design validation experiments for Phospho-NOS1 (Ser852) antibody specificity?

When validating the specificity of Phospho-NOS1 (Ser852) antibody, a comprehensive approach should include:

• Peptide competition assay:

  • Pre-incubate the antibody with the phosphorylated immunizing peptide

  • Run parallel Western blots with treated and untreated antibody

  • The phospho-specific band should disappear or be significantly reduced in the peptide-competed sample

• Phosphatase treatment:

  • Treat half of your protein sample with lambda phosphatase

  • Compare results with untreated sample

  • The phospho-specific signal should be eliminated in the phosphatase-treated sample

• Stimulation experiments:

  • Treat cells with agents known to affect nNOS phosphorylation (e.g., acetylcholine for 20 minutes should reduce Ser852 phosphorylation)

  • Include appropriate time points (e.g., 5, 10, 20, 30 minutes) to capture dynamics

  • Compare with baseline phosphorylation levels

• Cellular localization:

  • Perform immunofluorescence studies to confirm expected subcellular localization

  • In vascular endothelial cells, observe translocation patterns after stimulation

  • Compare with total nNOS staining patterns

These validation approaches ensure the reliability of experimental results and are essential when publishing research involving phospho-specific antibodies .

How can I investigate the functional consequences of altered NOS1 Ser852 phosphorylation in cardiovascular disease models?

To study the functional consequences of altered NOS1 Ser852 phosphorylation in cardiovascular disease, implement a multi-level experimental approach:

• In vivo modulation of phosphorylation state:

  • Use eNOS silenced mice to isolate nNOS-dependent effects

  • Employ pharmacological interventions (PP1/PP2 inhibitors, PKA modulators)

  • Monitor vascular relaxation responses and blood pressure changes

• Ex vivo functional assays:

  • Aortic ring preparations to measure relaxation responses

  • Compare responses in control vs. disease models (e.g., diabetes, hypertension)

  • Quantify NO and H₂O₂ concentrations in response to acetylcholine stimulation

• Molecular analysis of signaling pathways:

  • Assess PP1 translocation in diseased vs. healthy tissue

  • Examine NIPP1/PP1 interaction dynamics

  • Quantify phosphorylation levels using Western blot with phospho-specific antibodies

• Spatial dynamics analysis:

  • Track nNOS translocation to perinuclear regions using immunofluorescence

  • Correlate translocation with phosphorylation status

  • Compare patterns between healthy and diseased tissues

This comprehensive approach allows for mechanistic insights into how alterations in nNOS Ser852 phosphorylation contribute to vascular dysfunction in cardiovascular diseases .

What are the nuances of NOS1 Ser852 phosphorylation across different tissue types and disease states?

The regulation and functional significance of NOS1 Ser852 phosphorylation exhibits tissue-specific and disease-state differences:

• Vascular endothelium:

  • Dephosphorylation of Ser852 is associated with increased NO production and vasodilation

  • This pathway represents a protective mechanism in vascular function

  • Alterations are observed in diabetes and other cardiovascular diseases

• Medullary thick ascending limb (mTAL):

  • In diabetic models, PP2B-dependent regulation of NOS1 activity occurs

  • Interestingly, research shows no change in Ser852 phosphorylation in diabetic mTAL tissue

  • This suggests alternative regulatory mechanisms in renal tissue compared to vascular tissue

• Neuronal tissue:

  • In hypothalamic neurons, PP2B has been reported to dephosphorylate NOS1 at Ser852

  • The functional consequences in neuronal tissue may differ from vascular effects

  • This indicates context-dependent regulation of NOS1 activity

• Skeletal muscle:

  • NOS1 is localized beneath the sarcolemma of fast-twitch muscle fibers

  • Associates with the dystrophin glycoprotein complex

  • Role of Ser852 phosphorylation in this context remains to be fully characterized

These tissue-specific differences highlight the importance of considering cellular context when interpreting results related to NOS1 Ser852 phosphorylation .

How can I design experiments to monitor real-time changes in NOS1 Ser852 phosphorylation?

Designing experiments to monitor real-time changes in NOS1 Ser852 phosphorylation requires sophisticated approaches:

• Phospho-specific FRET biosensors:

  • Design or utilize FRET-based biosensors containing the NOS1 Ser852 region

  • Express in relevant cell types (endothelial cells, neurons)

  • Monitor real-time changes in phosphorylation upon stimulation

  • Correlate with functional readouts (NO production, calcium signaling)

• Time-course phosphorylation analysis:

  • Stimulate cells with acetylcholine or other relevant agonists

  • Collect samples at multiple time points (e.g., 0, 5, 10, 15, 20, 30 minutes)

  • Analyze phosphorylation status using Western blot with phospho-specific antibodies

  • Correlate with PP1 translocation and activation status

• Integrative live-cell imaging:

  • Combine phospho-specific immunofluorescence with NO indicators (e.g., DAF-FM)

  • Use fixed timepoint imaging after various stimulation periods

  • Analyze co-localization of phosphorylated NOS1 with relevant cellular structures

  • Track translocation events in parallel with phosphorylation changes

• Phosphoproteomics approach:

  • Perform quantitative phosphoproteomics at different timepoints after stimulation

  • Enrich for NOS1 phosphopeptides

  • Identify changes in multiple phosphorylation sites simultaneously

  • Map kinetics of Ser852 phosphorylation relative to other modifications

These approaches provide complementary information about the dynamics and functional significance of NOS1 Ser852 phosphorylation in various experimental systems .

What are common technical challenges when working with Phospho-NOS1 (Ser852) antibody?

When working with Phospho-NOS1 (Ser852) antibody, researchers should anticipate and address several technical challenges:

• Specificity concerns:

  • Cross-reactivity with other phosphorylated proteins is possible

  • Always include appropriate controls (phosphopeptide competition, phosphatase treatment)

  • Validate results with multiple detection methods when possible

• Low signal issues:

  • NOS1 expression levels vary significantly across tissues

  • Optimize protein extraction protocols for your specific tissue/cell type

  • Consider using enrichment approaches (immunoprecipitation prior to Western blot)

  • Adjust antibody concentration and incubation conditions based on your sample

• High background:

  • Optimize blocking conditions (consider 3-5% BSA instead of milk for phospho-epitopes)

  • Increase washing steps in PBS-T (0.1% Tween-20)

  • Try different secondary antibodies or detection systems

  • Reduce antibody concentration if background remains high

• Storage and stability issues:

  • Avoid repeated freeze-thaw cycles

  • Store at -20°C in aliquots

  • Include 50% glycerol, 0.5% BSA, and 0.02% sodium azide for stability

  • Check for precipitation before use

Addressing these challenges systematically will improve experimental outcomes when working with Phospho-NOS1 (Ser852) antibody .

How can I optimize detection of phosphorylated NOS1 in different sample types?

Optimizing detection of phosphorylated NOS1 requires sample-specific considerations:

• Tissue homogenates:

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Process samples quickly and keep cold throughout

  • Optimize homogenization buffer (consider RIPA buffer with 1% NP-40, 0.5% sodium deoxycholate)

  • For best results, prepare fresh samples rather than using frozen tissue

• Cultured cells:

  • Harvest cells directly in hot Laemmli buffer for immediate phospho-protein preservation

  • Alternatively, use phosphatase inhibitor cocktails during conventional lysis

  • Consider cell-type specific extraction protocols (e.g., endothelial cells vs. neurons)

  • Standardize cell confluence and stimulation conditions

• Immunohistochemistry optimization:

  • Test multiple antigen retrieval methods (citrate pH 6.0 vs. EDTA pH 9.0)

  • Increase antibody concentration (1:100-1:300 range) compared to Western blot

  • Include longer primary antibody incubation (overnight at 4°C)

  • Use amplification systems (biotin-streptavidin, tyramide) for low abundance targets

• Application-specific dilution table:

These optimization strategies enhance the detection sensitivity and specificity of phosphorylated NOS1 across different experimental systems .

How is Phospho-NOS1 (Ser852) measurement being applied in cardiovascular disease research?

Phospho-NOS1 (Ser852) measurement is emerging as a valuable tool in cardiovascular disease research:

• Endothelial dysfunction mechanisms:

  • Altered nNOS Ser852 phosphorylation status serves as a molecular marker for endothelial dysfunction

  • Studies show that acetylcholine-induced vasodilation involves nNOS Ser852 dephosphorylation

  • This pathway is particularly important in eNOS-compromised states, suggesting a compensatory mechanism

• Diabetes vascular complications:

  • In diabetic models, nNOS regulation through phosphorylation shows significant alterations

  • Research demonstrates that PP1/PP2-dependent pathways affecting nNOS phosphorylation are disrupted

  • These changes contribute to vascular dysfunction in diabetes

• Therapeutic target exploration:

  • Compounds affecting the cAMP/PKA/PP1 pathway may modulate nNOS activity through Ser852 phosphorylation

  • This presents potential targets for therapies aimed at restoring normal endothelial function

  • Measurement of phospho-nNOS serves as a biomarker for treatment efficacy

• Integration with redox signaling research:

  • Research shows interplay between nNOS-derived NO and H₂O₂ production

  • Phosphorylation status at Ser852 affects this balance

  • This has implications for oxidative stress in cardiovascular pathologies

These applications demonstrate the growing importance of Phospho-NOS1 (Ser852) measurement in understanding cardiovascular disease mechanisms and developing targeted interventions .

What are the latest methodological advances for studying NOS1 phosphorylation dynamics?

Recent methodological advances have enhanced our ability to study NOS1 phosphorylation dynamics:

• Mass spectrometry-based approaches:

  • Targeted phosphoproteomics allows simultaneous monitoring of multiple NOS1 phosphorylation sites

  • Parallel reaction monitoring (PRM) techniques provide quantitative analysis of specific phosphopeptides

  • These methods offer higher specificity than antibody-based detection

  • They enable discovery of novel phosphorylation sites regulating NOS1 activity

• Combined imaging techniques:

  • Super-resolution microscopy combined with phospho-specific antibodies

  • Allows visualization of subcellular distribution of phosphorylated NOS1

  • Can be paired with proximity ligation assays to study interactions with regulatory proteins

  • Enables spatiotemporal analysis of phosphorylation events at the nanoscale level

• Genetic approaches:

  • CRISPR-Cas9 gene editing to create phospho-mimetic (S852D) or phospho-null (S852A) NOS1 mutations

  • Expression of these mutants allows direct assessment of functional consequences

  • Can be implemented in relevant cell types or animal models

  • Provides definitive evidence for phosphorylation-specific effects

• Computational modeling:

  • Integration of experimental phosphorylation data into structural models of NOS1

  • Prediction of how Ser852 phosphorylation affects protein conformation and activity

  • Network analysis of signaling pathways regulating NOS1 phosphorylation

  • In silico screening of compounds that may modulate the phosphorylation state

These methodological advances are expanding our understanding of the complex regulation of NOS1 through phosphorylation and its implications in various physiological and pathological contexts .